Key facts
- This page summarizes SoYoung Kwon's Form 4 filing for Aptevo Therapeutics Inc. (APVO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 07 Jun 2022, 17:24.
SoYoung Kwon - 07 Jun 2022 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)
- Reporting relationship
- SVP, GC and Corporate Affairs
- Issuer ticker
- APVO
- Reported as of
- 07 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2022, 17:24:24 UTC
- Prior SEC filing
- 03 Jun 2022
- Next SEC filing
- 10 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- SoYoung Kwon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
SoYoung Kwon filed Form 4 for Aptevo Therapeutics Inc. (APVO) on 07 Jun 2022.
Change
- Previous filing in this sequence was filed on 03 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APVO
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +11,000
- Change %
- Price
- $0.000000
- Shares after
- 11,000
- Date
- 07 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,000
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
As previously disclosed in a Form 4 filed on March 4, 2022, the reporting person was granted 11,000 options on such date. At the time of the grant, there were insufficient shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan to make the full grant of equity award to the reporting person that was approved for issuance by Aptevo Therapeutics Inc.'s Compensation Committee. As such, the equity award was split into two separate grants with the first portion of 11,000 options granted on March 4, 2022 and the second portion of 11,000 restricted stock units granted on June 7, 2022, following stockholder approval of an increase in shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (as Amended and Restated).
Footnote F2
Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
Footnote F3
The RSU vests in three approximately equal annual installments beginning on March 3, 2023.